65180 Federal Register / Vol. 88, No. 182 / Thursday, September 21, 2023 / Notices 

9. Japanese Patent No. 6742991 issued 

August 19, 2020, entitled ‘‘Anti-Human 

Papillomavirus 16 E7 T Cell Receptors’’ 

[HHS Reference No. E–176–2014–0–JP– 

09]; 

10. Korean Patent No. 10–2445667 

issued September 16, 2022, entitled 

‘‘Anti-Human Papillomavirus 16 E7 T 

Cell Receptors’’ [HHS Reference No. E– 

176–2014–0–KR–10]; 

11. Mexican Patent No. 375379 issued 

September 25, 2020, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176– 

2014–0–MX–11]; 

12. Saudi Arabian Patent No. 7456 

issued January 5, 2021, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176– 

2014–0–SA–12]; 

13. United States Patent No. 

10,174,098 issued January 8, 2019, 

entitled ‘‘Anti-Human Papillomavirus 

16 E7 T Cell Receptors’’ [HHS Reference 

No. E–176–2014–0–US–13]; 

14. Hong Kong Patent No. HK1236203 

issued January 8, 2021, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176– 

2014–0–HK–14]; 

15. United States Patent No. 

10,870,687 issued December 22, 2020, 

entitled ‘‘Anti-Human Papillomavirus 

16 E7 T Cell Receptors’’ [HHS Reference 

No. E–176–2014–0–US–15]; 

16. European Patent Application No. 

19217074.4 filed December 17, 2019, 

entitled ‘‘Anti-Human Papillomavirus 

16 E7 T Cell Receptors’’ [HHS Reference 

No. E–176–2014–0–EP–16]; 

17. Australian Patent No. 2019283892 

issued May 13, 2021, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176– 

2014–0–AU–17]; 

18. Japanese Patent No. 6997267 

issued December 20, 2021, entitled 

‘‘Anti-Human Papillomavirus 16 E7 T 

Cell Receptors’’ [HHS Reference No. E– 

176–2014–0–JP–53]; 

19. Saudi Arabian Patent Application 

No. 520412601 filed August 10, 2020, 

entitled ‘‘Anti-Human Papillomavirus 

16 E7 T Cell Receptors’’ [HHS Reference 

No. E–176–2014–0–SA–54]; 

20. Hong Kong Patent Application No. 

42020020661.3 filed November 24, 

2020, entitled ‘‘Anti-Human 

Papillomavirus 16 E7 T Cell Receptors’’ 

[HHS Reference No. E–176–2014–0– 

HK–55]; 

21. Mexican Patent Application No. 

MX/a/2020/010035 filed September 24, 

2020, entitled ‘‘Anti-Human 

Papillomavirus 16 E7 T Cell Receptors’’ 

[HHS Reference No. E–176–2014–0– 

MX–56]; 

22. United States Patent No. 

11,434,272 issued September 6, 2020, 

entitled ‘‘Anti-Human Papillomavirus 

16 E7 T Cell Receptors’’ [HHS Reference 

No. E–176–2014–0–US–57]; 

23. Australian Patent No. 2021202227 

issued February 23, 2023, entitled 

‘‘Anti-Human Papillomavirus 16 E7 T 

Cell Receptors’’ [HHS Reference No. E– 

176–2014–0–AU–58]; 

24. Chinese Patent Application No. 

20210399056.9 filed April 14, 2021, 

entitled ‘‘Anti-Human Papillomavirus 

16 E7 T Cell Receptors’’ [HHS Reference 

No. E–176–2014–0–CN–59]; 

25. Israeli Patent No. 282518 issued 

July 2, 2022, entitled ‘‘Anti-Human 

Papillomavirus 16 E7 T Cell Receptors’’ 

[HHS Reference No. E–176–2014–0–IL– 

60]; 

26. Hong Kong Patent Application No. 

42022046605.6 filed January 19, 2022, 

entitled ‘‘Anti-Human Papillomavirus 

16 E7 T Cell Receptors’’ [HHS Reference 

No. E–176–2014–0–HK–62]; 

27. Japanese Patent No. 7291196 

issued June 6, 2023, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176– 

2014–0–JP–63]; 

28. Israeli Patent Application No. 

290655 filed February 16, 2022, entitled 

‘‘Anti-Human Papillomavirus 16 E7 T 

Cell Receptors’’ [HHS Reference No. E– 

176–2014–0–IL–64]; 

29. United States Patent Application 

No. 17/816,496 filed August 1, 2022, 

entitled ‘‘Anti-Human Papillomavirus 

16 E7 T Cell Receptors’’ [HHS Reference 

No. E–176–2014–0–US–65]; 

30. Korean Patent Application No. 

2022–7032043 filed September 15, 2022, 

entitled ‘‘Anti-Human Papillomavirus 

16 E7 T Cell Receptors’’ [HHS Reference 

No. E–176–2014–0–KR–66]; 

31. Australian Patent Application No. 

2023200608 filed February 6, 2023, 

entitled ‘‘Anti-Human Papillomavirus 

16 E7 T Cell Receptors’’ [HHS Reference 

No. E–176–2014–0–AU–01]; and 

32. Japanese Patent Application No. 

2023–091878 filed June 2, 2023, entitled 

‘‘Anti-Human Papillomavirus 16 E7 T 

Cell Receptors’’ [HHS Reference No. E– 

176–2014–0–JP–01]. 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to the 

following: 

‘‘Development, manufacture and 

commercialization of autologous T cell 

therapy products that are genetically 

engineered to have stable expression of 

a T cell receptor (TCR) targeting human 

papillomavirus (‘‘HPV’’)–16 E7, as 

claimed in the Licensed Patent Rights, 

for the treatment of HPV-associated 

cancers and premalignant conditions in 

humans.’’ 

The E–176–2014 patent family is 

primarily directed to an isolated TCR 

reactive to HPV 16 E7 antigen in the 

context of HLA–A*02. HPV describes a 

group of human viruses known to cause 

malignancy. Of the group, HPV–16 is 

the most prevalent strain. 

Approximately 90% of adults are 

estimated to have been exposed at some 

point in their lifetime. HPV drives 

transformation of infected cells through 

the expression of certain oncoproteins, 

chiefly E5, E6 and E7. The latter two are 

constitutively expressed in malignant 

cells and are necessary to maintain a 

transformed state, rendering them useful 

therapeutic targets. 

This Notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published Notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information from these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: September 18, 2023. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2023–20487 Filed 9–20–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 182 / Thursday, September 21, 2023 / Notices 65181 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Review of 

Institutional Training Grants (T32) in 

Digestive Diseases and Nutrition. 

Date: October 17, 2023. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

NIDDK, Democracy II, Suite 7000A, 6707 

Democracy Boulevard, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Tori Stone, Ph.D., 

Scientific Review Officer, NIDDK/Scientific 

Review Branch, National Institutes of Health, 

6707 Democracy Blvd., Bethesda, MD 20892, 

(301) 827–0994, tori.stone@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: September 15, 2023. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–20438 Filed 9–20–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Board of Scientific 

Counselors, National Institute of 

Neurological Disorders and Stroke. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), title 5 U.S.C., as amended for 

the review, discussion, and evaluation 

of individual intramural programs and 

projects conducted by the National 

Institute of Neurological Disorders and 

Stroke, including consideration of 

personnel qualifications and 

performance, and the competence of 

individual investigators, the disclosure 

of which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Board of Scientific 

Counselors, National Institute of 

Neurological Disorders and Stroke. 

Date: October 17, 2023. 

Time: 2:00 p.m. to 5:30 p.m. 

Agenda: To review and evaluate personnel 

qualifications and performance, and 

competence of individual investigators. 

Place: Porter Neuroscience Research 

Center, Building 35A, 35 Convent Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Date: October 23–24, 2023. 

Time: October 23, 2023, 8:30 a.m. to 9:00 

p.m.; October 24, 2023, 9:00 a.m. to 12:30 

p.m. 

Agenda: To review and evaluate personnel 

qualifications and performance, and 

competence of individual investigators. 

Place: The Bethesdan Hotel, 8120 

Wisconsin Avenue, Bethesda, Maryland 

20814 (Hybrid Meeting). 

Contact Person: Jeffrey S. Diamond, Ph.D., 

Scientific Director, c/o Caren Collins, 

National Institute of Neurological Disorders 

and Stroke, NIH, Building 35, Room GF–149, 

Bethesda, MD 20892, 301–435–1896, 

diamondj@ninds.nih.gov; collinsca@

ninds.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: September 15, 2023. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–20420 Filed 9–20–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIHAI75N93023R00003: 

Pre-clinical Models of Infectious Diseases— 

Task Area B. 

Date: October 20–23, 2023. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3E70A, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Annie Walker-Abbey, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3E70A, 

Rockville, MD 20852, 240–627–3390, 

aabbey@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 18, 2023. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–20493 Filed 9–20–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Human Liver and 

Human Liver Cells Research Resource. 

Date: November 17, 2023. 

Time: 12:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

NIDDK, Democracy II, Suite 7000A, 6707 


ddrumheller on DSK120RN23PROD with NOTICES1